1. Home
  2. ESE vs IBRX Comparison

ESE vs IBRX Comparison

Compare ESE & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$234.57

Market Cap

5.2B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.16

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESE
IBRX
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ESE
IBRX
Price
$234.57
$6.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$237.50
$11.80
AVG Volume (30 Days)
174.9K
52.8M
Earning Date
02-05-2026
03-02-2026
Dividend Yield
0.14%
N/A
EPS Growth
193.06
N/A
EPS
11.55
N/A
Revenue
$1,095,388,000.00
$82,555,000.00
Revenue This Year
$18.95
$680.06
Revenue Next Year
$6.91
$90.18
P/E Ratio
$20.18
N/A
Revenue Growth
19.18
1025.95
52 Week Low
$128.59
$1.83
52 Week High
$234.43
$8.28

Technical Indicators

Market Signals
Indicator
ESE
IBRX
Relative Strength Index (RSI) 72.68 67.79
Support Level $219.35 $5.67
Resistance Level $229.41 $6.75
Average True Range (ATR) 5.54 0.89
MACD 1.42 0.02
Stochastic Oscillator 94.69 60.90

Price Performance

Historical Comparison
ESE
IBRX

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: